CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.
June 19th 2019
Although palliative care has been shown to improve survival rates among patients with metastatic renal cell carcinoma, its utilization remains low while certain barriers and disparities still exist.
June 17th 2019
A novel imaging test developed at UT Southwestern may help to determine which patients with kidney cancer would benefit from treatment with immunotherapy.
June 13th 2019
An international study of nearly 2,000 patients with renal cell carcinoma exposed many unmet needs across all stages of disease.
May 22nd 2019
Patients with advanced renal cell carcinoma have new first-line therapy options.
May 15th 2019
The Food and Drug Administration approved the combination use of Bavencio plus Inlyta for the first-line treatment of patients with advanced renal cell carcinoma.
May 10th 2019
With the growing price of cancer treatment, researchers evaluated the cost-effectiveness of the new standard-of-care in frontline metastatic renal cell carcinoma.
May 9th 2019
Kidney cancer survivors who follow recommendations for physical activity experience improved quality of life, but few individuals adhere to the guidelines, according to recent findings.
April 29th 2019
With patient resistance to single-agent immunotherapies in the treatment of advanced renal cell carcinoma, new combination therapies are needed in the frontline setting.
April 24th 2019
A person’s pre-existing mental state may negatively influence their health, but professional support can help maintain the best mindset, say researchers.
April 22nd 2019
The Food and Drug Administration approved Keytruda in combination with Inlyta for the frontline treatment of patients with advanced renal cell carcinoma.
April 19th 2019
The combination use of Keytruda plus Inlyta significantly improved survival outcomes among patients with previously untreated advanced renal cell carcinoma – the most common type of kidney cancer.
March 25th 2019
There is still work to do in the field of molecular diagnosis for renal cell carcinoma, according to David I. Quinn, MBBS, Ph.D., FRACP, FACP.
March 25th 2019
An expert discusses the evolving treatments for renal cell carcinoma (RCC) over the last decade, as well as the future role of immunotherapies for patients with RCC.
March 11th 2019
In conjunction with Kidney Cancer Awareness Month, learn more about risk factors and treatment options for the disease.
March 7th 2019
In this week’s episode, we spoke with a patient advocate and survivor of renal cell carcinoma to help raise awareness during Kidney Cancer Awareness month.
March 6th 2019
Frontline use of Bavencio (avelumab) plus Inlyta (axitinib) significantly improved progression-free survival compared with the standard of care in patients with advanced renal cell carcinoma.
February 25th 2019
CURE® spoke with a researcher from the American Cancer Society to examine temporal trends of obesity-related cancers in younger adults.
February 15th 2019
The Food and Drug Administration granted a priority review to Keytruda (pembrolizumab) in combination with Inlyta (axitinib) as a frontline treatment for advanced renal cell carcinoma.
February 12th 2019
The Food and Drug Administration granted a priority review to Bavencio (avelumab) in combination with Inlyta (axitinib) to treat patients with advanced renal cell carcinoma (RCC).
January 28th 2019
Meeting combined exercise guidelines improved quality of life in kidney cancer survivors; however, few individuals reported that they actually follow such guidelines.
January 25th 2019
Yervoy plus Opdivo is a good combination for many patients with kidney cancer, though some individuals should steer clear of the regimen.
January 25th 2019
Certain factors – such as diastolic blood pressure and fasting insulin – were found to be associated with renal cell carcinoma.
January 15th 2019
People who have experienced high exposures to gasoline might be at an increased risk for kidney cancer, according to recent research.
January 14th 2019
Treatment side effects are typically manageable for patients with metastatic kidney cancer, but patients must have open communication with their health care team about them.
January 10th 2019
A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.
November 19th 2018
The phase 3 TIVO-3 trial – designed to evaluate the efficacy of Fotivda in patients with renal cell carcinoma – met its primary endpoint of improved progression-free survival.